What is Sensorium Therapeutics?
Sensorium Therapeutics operates as a clinical-stage biotechnology enterprise dedicated to addressing the significant unmet needs in brain and mental health. The company distinguishes itself through an AI-driven discovery engine that mines natural product chemistry to develop novel therapeutics for complex conditions such as epilepsy, anxiety, and Alzheimer's disease. By integrating machine learning with traditional medicinal chemistry, Sensorium aims to bypass the limitations of conventional drug development, offering more precise and effective interventions for patients suffering from chronic neurological disorders. Their market position is defined by a commitment to high-quality science and a strategic focus on high-impact therapeutic areas.
How much funding has Sensorium Therapeutics raised?
Sensorium Therapeutics has raised a total of $55M across 2 funding rounds:
Series A
$30M
Series A
$25M
Series A (2022): $30M with participation from Santé Ventures, CU Healthcare Innovation Fund, and Route 66 Ventures
Series A (2025): $25M led by Dolby Family Ventures, Hatteras Venture Partners, Mockingbird Credit Partners, and Mission BioCapital
Key Investors in Sensorium Therapeutics
Dolby Family Ventures
Dolby Family Ventures is an investment firm focused on supporting early-stage companies that address significant science and engineering challenges, particularly in the biotech and pharmaceutical sectors.
Hatteras Venture Partners
Hatteras Venture Partners is a venture capital firm focused on building transformative companies in the biotech, MedTech, and HealthTech sectors, partnering with visionary founders to invest in innovative healthcare solutions.
Mission BioCapital
Mission BioCapital is a venture capital firm that provides early-stage capital to innovative life science entrepreneurs, focusing on empowering startups through mentorship and a commitment to accelerating scientific breakthroughs.
What's next for Sensorium Therapeutics?
With this latest capital deployment, Sensorium Therapeutics is poised to scale its clinical operations and deepen its research into neuro-circuitry modulation. The strategic focus will likely shift toward optimizing lead candidates for human trials and strengthening the company's intellectual property portfolio. As the firm continues to navigate the complexities of drug development, the backing from specialized life science investors will be instrumental in facilitating regulatory milestones and potential future partnerships. The company remains focused on its mission to transform the landscape of mental health treatment through data-backed, nature-inspired innovation.
See full Sensorium Therapeutics company page
